Hot Investor Mandate: China-Focused VC Fund Invests Up to $25M, Most Interested in Therapeutics in Oncology and Metabolic Disorders

5 Aug

A sector-exclusive life sciences venture and growth equity fund focused on Asia has offices in USA, Hong Kong, and China. The firm is investing from its fifth fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. The firm focuses on China but also considers opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: